The persisting effects of electroconvulsive stimulation on the hippocampal proteome

O’Donovan, Sinead M.; O’Mara, Shane M.; Dünn, Michael J.; McLoughlin, Declan M.

doi:10.1016/j.brainres.2014.10.020

Cited by 1 publication

(2 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11, 12 Prior to 2D-DIGE analysis, 85–90% of the six most abundant proteins found in human plasma (albumin, IgG, IgA, transferrin, haptoglobin and antitrypsin) were removed, yielding two protein fractions from each plasma sample: low-abundance and high-abundance proteins. Differentially expressed protein spots were targeted for identification by mass spectrometry based on their statistical significance ( P <0.05), their location/shape following a comparison of CyDye-labeled gel images, and manual inspection of silver-stained preparative gels.…”

Section: Methodsmentioning

confidence: 99%

“…10 Using proteomic analyses, we and others have shown that ECS induces a wide range of changes in rodent brain and blood proteomes, including changes in acute phase proteins, carrier proteins, cell signaling proteins, neurotrophic factors, and persisting changes in cytoskeletal and metabolism-related proteins. 11, 12, 13, 14 However, to our knowledge, there has only been one relatively small pilot study ( n =12) carried out to date investigating the serum proteome of depressed patients receiving treatment with ECT. 15 After a single ECT treatment, changes in serum proteins and small molecules were identified, with changes in platelet factor 4 significantly related to symptom improvement.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Electroconvulsive therapy modulates plasma pigment epithelium-derived factor in depression: a proteomics study

et al. 2017

View full text Add to dashboard Cite

Electroconvulsive therapy (ECT) is the most effective treatment for severe depression, yet its mechanism of action is not fully understood. Peripheral blood proteomic analyses may offer insights into the molecular mechanisms of ECT. Patients with a major depressive episode were recruited as part of the EFFECT-Dep trial (enhancing the effectiveness of electroconvulsive therapy in severe depression; ISRCTN23577151) along with healthy controls. As a discovery-phase study, patient plasma pre-/post-ECT (n=30) was analyzed using 2-dimensional difference in gel electrophoresis and mass spectrometry. Identified proteins were selected for confirmation studies using immunodetection methods. Samples from a separate group of patients (pre-/post-ECT; n=57) and matched healthy controls (n=43) were then used to validate confirmed changes. Target protein mRNA levels were also assessed in rat brain and blood following electroconvulsive stimulation (ECS), the animal model of ECT. We found that ECT significantly altered 121 protein spots with 36 proteins identified by mass spectrometry. Confirmation studies identified a post-ECT increase (P<0.01) in the antiangiogenic and neuroprotective mediator pigment epithelium-derived factor (PEDF). Validation work showed an increase (P<0.001) in plasma PEDF in depressed patients compared with the controls that was further increased post-ECT (P=0.03). PEDF levels were not associated with mood scores. Chronic, but not acute, ECS increased PEDF mRNA in rat hippocampus (P=0.02) and dentate gyrus (P=0.03). This study identified alterations in blood levels of PEDF in depressed patients and further alterations following ECT, as well as in an animal model of ECT. These findings implicate PEDF in the biological response to ECT for depression.

show abstract

Section: Methodsmentioning

confidence: 99%